Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Westenberg maintains an Overweight rating on Adaptive Biotechnologies (NASDAQ:ADPT) but lowers the price target from $15 to $14.
August 08, 2023 | 7:17 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Adaptive Biotechnologies' price target has been lowered from $15 to $14 by Piper Sandler, though the Overweight rating is maintained.
The lowering of the price target by Piper Sandler could potentially lead to a negative sentiment among investors, which may put downward pressure on the stock price in the short term. However, the maintained Overweight rating indicates that the analyst still sees potential in the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100